Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : WR's Momentum Trades -- Ignore unavailable to you. Want to Upgrade?

To: Impeccable who wrote (3557)	1/28/1999 7:54:00 PM
From: E. M. Edds	Read Replies (1) \| Respond to of 11130

From www.otcfn.com/celn On October 14, 1998, Celsion announced that it is beginning phase one clinical human trials of its benign prostatic hyperplasia treatment system (BPH) - to relieve the urinary obstruction condition which >50% of men over 55 experience. Several key elements position CELN's system to dramatically increase the BPH treatment market which is currently $3 billion in the U.S. and $9 billion worldwide.